Hub : Traits :

Medication: Blood pressure

382 significantly associated models · 127 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	11181327	12600396	2	1	6.2e-13	1.2e-12	3.5e-04	75	CLCN6
2	1	26428864	27820430	1	1	4.2e-08	9.2e-06	2.2e-01	92	PIGV
3	1	88621347	90053563	1	1	7.8e-09	2.2e-08	1.1e-01	92	GTF2B
4	1	112312154	114196883	6	4	7.3e-18	4.0e-15	3.9e-01	99	CAPZA1 RHOC SLC16A1 WNT2B
5	1	230142626	231548480	1	1	3.0e-14	1.4e-13	1.0e+00	100	AGT
6	2	24021231	25692112	1	1	4.9e-08	5.2e-07	2.7e-07	-5	NCOA1
7	2	26223547	27689899	3	2	5.5e-09	5.5e-26	4.7e-17	37	KCNK3 SLC35F6
8	2	215101843	216697115	1	1	1.2e-07	2.2e-04	8.6e-03	50	ABCA12
9	3	26720690	28211713	1	1	3.9e-08	2.7e-09	2.3e-02	85	SLC4A7
10	3	137189600	138819532	2	1	5.7e-08	1.7e-07	1.0e+00	100	DBR1
11	4	80488345	82578407	2	1	1.4e-09	2.7e-26	3.0e-18	33	C4orf22
12	5	130830617	132425049	5	1	7.7e-08	8.2e-08	1.0e+00	100	SLC22A5
13	6	33856903	35362848	1	1	1.0e-07	5.3e-05	2.9e-02	71	C6orf106
14	6	42611872	44034691	2	1	5.4e-10	6.7e-10	1.0e+00	100	ZNF318
15	6	125970401	127355237	1	1	7.2e-11	4.7e-20	6.1e-14	33	CENPW
16	7	6502367	7988091	1	1	9.4e-10	1.0e-07	6.3e-01	99	C1GALT1
17	7	26969253	27533292	2	1	2.7e-14	1.8e-14	2.4e-02	91	HOXA10
18	7	129917130	131315092	1	1	3.1e-11	3.8e-14	3.0e-06	62	RP11-138A9.1
19	8	8092025	13120332	17	2	3.6e-10	2.8e-10	1.2e-03	74	FAM167A NEIL2
20	10	18221643	19074958	1	1	4.9e-08	1.4e-10	4.2e-10	5	CACNB2
21	10	103987875	105647095	2	1	2.1e-08	4.4e-09	7.9e-02	91	NT5C2
22	10	115555541	116053000	1	1	5.7e-08	2.1e-11	1.6e-05	58	ADRB1
23	11	1213806	2705175	5	8	1.2e-15	8.7e-17	NaN	NaN	LOC100133545 LSP1 MRPL23-AS1 TNNT3
24	11	46570859	47977454	2	1	3.3e-09	4.8e-08	3.6e-01	97	ACP2
25	11	65157820	65733393	2	2	2.1e-09	3.8e-09	1.9e-02	84	RNASEH2C SIPA1
26	11	99859184	101559718	2	1	4.4e-19	3.7e-19	1.0e+00	100	ARHGAP42
27	12	111154626	113517494	8	1	1.4e-11	9.8e-16	1.6e-06	64	SH2B3
28	13	29386474	30865365	1	1	7.1e-08	9.8e-10	3.1e-04	65	SLC7A1
29	15	74042497	76108550	11	1	9.1e-11	9.5e-11	6.6e-02	92	MPI
30	15	80743350	81292020	1	1	1.2e-07	1.5e-10	3.0e-04	68	FAM108C1
31	15	90712555	92135418	2	1	2.5e-20	4.8e-17	5.4e-01	100	FES
32	16	3462595	5510848	5	2	5.0e-11	3.7e-10	1.3e-03	74	MGRN1 TRAP1
33	16	81230341	81993974	1	1	1.5e-08	1.1e-10	1.0e-05	53	CMIP
34	16	89013848	90172696	12	1	3.5e-12	1.9e-12	6.7e-02	93	CDK10
35	17	6644945	8484683	4	2	2.8e-08	5.7e-08	7.2e-01	100	CYB5D1 FGF11
36	17	42607368	43913030	6	2	1.2e-08	3.1e-07	9.8e-01	100	FMNL1 LRRC37A4P
37	17	44788310	45510971	2	1	9.4e-08	1.2e-06	1.8e-01	92	NSF
38	17	60858059	62259376	1	1	1.1e-08	1.1e-08	1.0e+00	100	ACE
39	17	78665405	80023050	1	1	9.4e-08	8.9e-08	3.4e-01	97	RP11-1055B8.4
40	19	16462417	18007950	2	1	4.2e-09	1.6e-08	9.7e-03	79	MYO9B
41	20	7419920	9648826	1	2	2.0e-09	6.4e-13	1.0e-03	79	PLCB1
42	20	57525478	58079512	1	1	1.1e-15	2.4e-22	3.2e-09	63	ZNF831
43	20	61667526	62912463	2	2	8.7e-09	2.1e-08	1.0e+00	100	LIME1 ZBTB46

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder or Schizophrenia	1.76	3	2	4.4	0.00	1.0e+00	CDK10 FES NT5C2
Depressed Affect (Nagel 2018)	2.50	5	4	8.9	0.30	6.2e-01	ACP2 FMNL1 LRRC37A4P NSF SH2B3
Depression (Nagel 2018)	1.42	1	0	0.0	0.00	1.0e+00	NSF
Intelligence (Savage-Jansen 2018)	1.03	2	0	0.0	0.00	1.0e+00	GTF2B LRRC37A4P
Neuroticism (Nagel 2018)	2.85	5	4	8.9	-0.08	9.0e-01	ACP2 FMNL1 LRRC37A4P NSF NT5C2
Schizophrenia (2018)	1.86	2	2	4.4	0.00	1.0e+00	FES NT5C2
Worry (Nagel 2018)	2.40	5	4	8.9	0.22	7.3e-01	C1GALT1 FMNL1 LRRC37A4P NSF NT5C2
Alzheimer’s Disease (including proxy)	1.03	1	1	2.2	0.00	1.0e+00	ACE
Crohns Disease (2017)	2.04	1	1	2.2	0.00	1.0e+00	SLC22A5
Irritable Bowel Disease (IBD)	1.88	2	1	2.2	0.00	1.0e+00	LSP1 SLC22A5
Reaction Time	1.07	1	1	2.2	0.00	1.0e+00	SH2B3
Breast Cancer	5.59	11	7	15.6	0.45	1.0e-01	FES FMNL1 LOC100133545 LRRC37A4P LSP1 MPI MRPL23-AS1 NSF SLC22A5 SLC4A7 TNNT3
Ovarian Cancer	1.79	2	1	2.2	0.00	1.0e+00	LRRC37A4P NSF
Prostate Cancer	1.69	1	0	0.0	0.00	1.0e+00	TNNT3
Body Mass Index (BMI) (2010)	1.70	1	0	0.0	0.00	1.0e+00	NT5C2
Coronary Artery Disease (CAD)	2.74	3	1	2.2	0.00	1.0e+00	C6orf106 DBR1 SH2B3
Crohns Disease (2012)	1.59	1	1	2.2	0.00	1.0e+00	SLC22A5
Fasting Glucose	1.73	1	1	2.2	0.00	1.0e+00	ACP2
HDL Cholesterol	2.52	7	3	6.7	-0.76	4.6e-02	ACP2 ADRB1 C6orf106 PIGV RNASEH2C RP11-138A9.1 SIPA1
LDL Cholesterol	1.82	4	0	0.0	-0.64	3.6e-01	C6orf106 MPI PIGV SH2B3
Neuroticism (2016)	2.61	5	2	4.4	-0.59	2.9e-01	FAM167A FMNL1 LRRC37A4P NEIL2 NSF
Primary Biliary Cirrhosis	1.99	3	1	2.2	0.00	1.0e+00	FMNL1 LRRC37A4P SH2B3
Rheumatoid Arthritis	1.00	1	0	0.0	0.00	1.0e+00	SH2B3
Schizophrenia (2014)	1.91	3	2	4.4	0.00	1.0e+00	CDK10 FES NT5C2
Triglycerides	1.52	1	0	0.0	0.00	1.0e+00	NEIL2
Type 2 Diabetes (T2D) (2012)	1.71	1	0	0.0	0.00	1.0e+00	RP11-138A9.1
Blood Eosinophil Count	5.96	10	8	17.8	0.78	7.9e-03	CLCN6 FMNL1 LRRC37A4P NSF PIGV RP11-138A9.1 SH2B3 SIPA1 SLC22A5 ZNF831
Blood Platelet Count	2.28	17	12	26.7	0.28	2.8e-01	CAPZA1 CDK10 GTF2B LIME1 MGRN1 MPI MYO9B PIGV RHOC RNASEH2C SH2B3 SLC16A1 SLC22A5 SLC4A7 TNNT3 WNT2B ZNF318
Blood Red Count	3.15	18	10	22.2	-0.02	9.4e-01	C4orf22 CDK10 CENPW CLCN6 CYB5D1 FMNL1 GTF2B LRRC37A4P MGRN1 MPI NCOA1 NSF NT5C2 RNASEH2C RP11-138A9.1 SH2B3 SLC35F6 ZBTB46
Blood White Count	3.12	19	7	15.6	0.52	1.9e-02	ABCA12 ARHGAP42 CDK10 CMIP CYB5D1 FES FMNL1 GTF2B KCNK3 LRRC37A4P MGRN1 NT5C2 PLCB1 RP11-1055B8.4 RP11-138A9.1 SH2B3 SLC22A5 SLC35F6 TRAP1
Heel T-Score	2.83	17	13	28.9	0.39	1.2e-01	ACP2 ARHGAP42 CAPZA1 CMIP CYB5D1 FMNL1 GTF2B LIME1 LRRC37A4P NCOA1 NSF NT5C2 RHOC RNASEH2C SIPA1 SLC16A1 ZNF318
BMI	1.52	9	4	8.9	0.53	1.4e-01	C4orf22 C6orf106 CMIP CYB5D1 FAM108C1 KCNK3 NT5C2 SLC35F6 ZNF318
Height	2.05	32	22	48.9	-0.25	1.7e-01	ACE ACP2 ADRB1 ARHGAP42 C6orf106 CACNB2 CAPZA1 CENPW DBR1 FES FGF11 GTF2B HOXA10 LRRC37A4P LSP1 MGRN1 NCOA1 NSF NT5C2 PIGV RHOC RNASEH2C RP11-1055B8.4 SH2B3 SIPA1 SLC16A1 SLC22A5 SLC35F6 SLC4A7 TRAP1 ZNF318 ZNF831
Waist Hip Ratio (WHR)	2.66	14	8	17.8	0.22	4.5e-01	CENPW CMIP DBR1 FGF11 GTF2B LRRC37A4P MYO9B NCOA1 NSF RNASEH2C RP11-138A9.1 SIPA1 SLC16A1 ZNF318
Systolic Blood Pressure	16.80	50	45	100.0	0.96	8.7e-30	ABCA12 ACE ACP2 ADRB1 AGT ARHGAP42 C1GALT1 C4orf22 CACNB2 CAPZA1 CENPW CLCN6 CMIP CYB5D1 DBR1 FAM108C1 FES FGF11 FMNL1 GTF2B HOXA10 LIME1 LOC100133545 LRRC37A4P LSP1 MGRN1 MPI MRPL23-AS1 MYO9B NCOA1 NEIL2 NSF NT5C2 PIGV PLCB1 RHOC RNASEH2C RP11-1055B8.4 RP11-138A9.1 SH2B3 SIPA1 SLC16A1 SLC4A7 SLC7A1 TNNT3 TRAP1 WNT2B ZBTB46 ZNF318 ZNF831
Smoking Status	1.43	3	0	0.0	0.00	1.0e+00	C6orf106 FAM108C1 FES
Allergy or Eczema	1.76	8	2	4.4	-0.05	9.1e-01	C6orf106 CLCN6 FES LIME1 MPI SH2B3 SIPA1 SLC22A5
Cardiovascular Disease	14.64	49	40	88.9	0.97	1.5e-34	ACE ACP2 ADRB1 AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 CACNB2 CAPZA1 CDK10 CENPW CLCN6 CMIP CYB5D1 DBR1 FAM108C1 FES FGF11 FMNL1 GTF2B HOXA10 KCNK3 LIME1 LOC100133545 LSP1 MGRN1 MPI MRPL23-AS1 MYO9B NCOA1 NT5C2 PIGV PLCB1 RHOC RNASEH2C RP11-1055B8.4 RP11-138A9.1 SH2B3 SIPA1 SLC22A5 SLC35F6 SLC4A7 TNNT3 TRAP1 WNT2B ZBTB46 ZNF318 ZNF831
Hypothyroidism (self reported)	2.81	1	1	2.2	0.00	1.0e+00	SH2B3
Respiratory disease	2.05	2	1	2.2	0.00	1.0e+00	FGF11 SLC22A5
Type 2 Diabetes (T2D) (2018)	2.30	7	0	0.0	0.99	1.2e-05	ACE C1GALT1 DBR1 RNASEH2C RP11-138A9.1 SH2B3 ZBTB46
Lung FEV1/FVC ratio	1.34	8	4	8.9	-0.46	2.5e-01	ARHGAP42 C1GALT1 C6orf106 CACNB2 CENPW LRRC37A4P NSF SLC22A5
Lung FVC	3.04	17	5	11.1	0.39	1.2e-01	ABCA12 C6orf106 CENPW CLCN6 DBR1 FGF11 FMNL1 HOXA10 LRRC37A4P NCOA1 NSF NT5C2 RP11-1055B8.4 SH2B3 SLC16A1 SLC22A5 ZBTB46
Neuroticism	2.82	7	4	8.9	0.11	8.1e-01	ACP2 C1GALT1 FGF11 FMNL1 LRRC37A4P NSF NT5C2
Chronotype (morning person)	1.21	1	0	0.0	0.00	1.0e+00	CAPZA1
Hair Pigment	8.86	14	8	17.8	0.24	4.1e-01	ACP2 ARHGAP42 C4orf22 C6orf106 CDK10 DBR1 FES LRRC37A4P PIGV RNASEH2C RP11-138A9.1 SH2B3 SIPA1 ZNF831
Tanning	9.90	3	1	2.2	0.00	1.0e+00	CDK10 CLCN6 SH2B3
Hand grip strength (left)	2.10	7	3	6.7	-0.44	3.3e-01	FES LRRC37A4P MGRN1 NSF RHOC SLC16A1 SLC22A5
Number of treatments/medications taken	4.87	13	3	6.7	0.96	2.0e-07	ACE ARHGAP42 C1GALT1 C6orf106 FAM108C1 FES MGRN1 NCOA1 RHOC SH2B3 SLC16A1 SLC22A5 ZNF831
Sensitivity / hurt feelings	3.23	4	4	8.9	-0.99	1.2e-02	FES FMNL1 LRRC37A4P NSF
Frequency of depressed mood in last 2 weeks	1.51	1	0	0.0	0.00	1.0e+00	NSF
Hearing difficulty/problems: Yes	1.59	1	1	2.2	0.00	1.0e+00	ZNF318
Relative age of first facial hair	3.15	5	4	8.9	0.72	1.7e-01	C4orf22 FMNL1 LRRC37A4P NSF SIPA1
Systolic blood pressure, automated reading	11.88	42	30	66.7	0.97	8.2e-29	ABCA12 ACP2 ADRB1 AGT ARHGAP42 C4orf22 CACNB2 CAPZA1 CLCN6 CMIP DBR1 FAM108C1 FAM167A FES FGF11 FMNL1 GTF2B HOXA10 LIME1 LOC100133545 LRRC37A4P LSP1 MGRN1 MPI MRPL23-AS1 MYO9B NCOA1 NEIL2 NSF NT5C2 PIGV RHOC RNASEH2C RP11-1055B8.4 SH2B3 SIPA1 SLC16A1 SLC4A7 TNNT3 TRAP1 ZBTB46 ZNF831
Angina	2.57	2	1	2.2	0.00	1.0e+00	FES ZBTB46
Vitamin and mineral supplements	1.16	1	0	0.0	0.00	1.0e+00	NSF
Medication: Metformin	1.64	3	0	0.0	0.00	1.0e+00	DBR1 RP11-138A9.1 ZBTB46
Impedance of leg (right)	2.10	15	8	17.8	0.01	9.8e-01	ARHGAP42 C6orf106 FAM108C1 FAM167A FES FMNL1 KCNK3 LRRC37A4P MYO9B NEIL2 NSF NT5C2 SLC16A1 SLC35F6 ZNF318
Leg fat-free mass (left)	2.02	13	6	13.3	0.05	8.6e-01	ARHGAP42 C6orf106 CENPW FAM108C1 FAM167A FES KCNK3 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Trunk fat percentage	2.38	14	7	15.6	0.07	7.9e-01	C6orf106 CDK10 DBR1 FAM108C1 FGF11 FMNL1 HOXA10 KCNK3 LRRC37A4P MRPL23-AS1 MYO9B NSF RP11-138A9.1 SLC16A1
Hand grip strength (right)	2.02	6	1	2.2	-0.43	3.9e-01	CAPZA1 LRRC37A4P NSF RHOC SLC16A1 SLC22A5
Fed-up feelings	2.30	7	2	4.4	-0.02	9.7e-01	ACP2 FAM167A FMNL1 LRRC37A4P NEIL2 NSF SH2B3
Relative age voice broke	2.09	3	3	6.7	0.00	1.0e+00	FMNL1 LRRC37A4P NSF
Taking other prescription medications	2.20	2	1	2.2	0.00	1.0e+00	SH2B3 ZNF318
Age when periods started (menarche)	1.84	3	0	0.0	0.00	1.0e+00	LRRC37A4P NEIL2 SLC22A5
Heel bone mineral density (BMD) T-score, automated (left)	2.95	8	5	11.1	0.37	3.6e-01	ACP2 CMIP CYB5D1 FAM167A NEIL2 RNASEH2C SIPA1 SLC16A1
Serious illness, injury or assault to yourself	1.37	1	0	0.0	0.00	1.0e+00	CMIP
High blood pressure	16.87	56	44	97.8	0.98	2.4e-43	ABCA12 ACE ACP2 ADRB1 AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 CACNB2 CAPZA1 CDK10 CENPW CLCN6 CMIP CYB5D1 DBR1 FAM108C1 FAM167A FES FGF11 FMNL1 GTF2B HOXA10 KCNK3 LIME1 LOC100133545 LRRC37A4P LSP1 MGRN1 MPI MRPL23-AS1 MYO9B NCOA1 NEIL2 NSF NT5C2 PIGV PLCB1 RHOC RNASEH2C RP11-1055B8.4 RP11-138A9.1 SH2B3 SIPA1 SLC16A1 SLC22A5 SLC35F6 SLC4A7 SLC7A1 TNNT3 TRAP1 WNT2B ZBTB46 ZNF318 ZNF831
Hayfever, allergic rhinitis or eczema	1.70	5	1	2.2	0.25	6.8e-01	C6orf106 CLCN6 LIME1 MPI SLC22A5
Supplements: Glucosamine	1.10	1	0	0.0	0.00	1.0e+00	MPI
Medication: Atenolol	7.40	9	2	4.4	0.99	4.4e-07	ADRB1 ARHGAP42 C4orf22 CLCN6 FES NCOA1 RHOC SH2B3 TRAP1
Medication: Levothyroxine sodium	2.77	2	1	2.2	0.00	1.0e+00	FAM167A SH2B3
Sitting height	1.68	13	8	17.8	0.32	2.9e-01	ADRB1 C6orf106 CENPW FGF11 GTF2B LRRC37A4P NSF PIGV RP11-1055B8.4 SLC22A5 SLC35F6 SLC4A7 ZNF831
High blood pressure (mother)	7.80	17	2	4.4	0.96	5.2e-10	ADRB1 AGT ARHGAP42 C4orf22 CDK10 CENPW DBR1 FES HOXA10 LSP1 NT5C2 PIGV RHOC SLC4A7 TNNT3 ZNF318 ZNF831
Body mass index (BMI)	1.52	7	5	11.1	0.75	5.4e-02	C6orf106 FAM108C1 FAM167A GTF2B KCNK3 NEIL2 NT5C2
Impedance of leg (left)	2.19	17	9	20.0	-0.02	9.3e-01	ARHGAP42 C6orf106 FAM108C1 FAM167A FES FMNL1 KCNK3 LRRC37A4P MYO9B NEIL2 NSF NT5C2 RHOC SLC16A1 SLC22A5 SLC35F6 ZNF318
Leg predicted mass (left)	2.01	13	6	13.3	0.06	8.5e-01	ARHGAP42 C6orf106 CENPW FAM108C1 FAM167A FES KCNK3 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Trunk fat mass	2.12	10	4	8.9	0.05	9.0e-01	C6orf106 DBR1 FAM108C1 HOXA10 KCNK3 LRRC37A4P NSF NT5C2 RP11-138A9.1 SLC16A1
Waist circumference	1.69	5	3	6.7	0.72	1.7e-01	C6orf106 CMIP FAM108C1 KCNK3 MPI
Number of incorrect matches in round	2.00	1	0	0.0	0.00	1.0e+00	FES
Past tobacco smoking	1.41	1	0	0.0	0.00	1.0e+00	SH2B3
Alcohol usually taken with meals	1.06	1	0	0.0	0.00	1.0e+00	FES
Nervous feelings	2.88	7	4	8.9	0.06	9.0e-01	C1GALT1 FAM167A FMNL1 LRRC37A4P NEIL2 NSF NT5C2
Frequency of tenseness / restlessness in last 2 weeks	2.28	4	3	6.7	-0.98	2.4e-02	FMNL1 LRRC37A4P NSF NT5C2
Hearing difficulty/problems with background noise	2.24	3	1	2.2	0.00	1.0e+00	LRRC37A4P NSF ZNF318
Hair/balding pattern: Pattern 2	2.89	5	2	4.4	-0.72	1.7e-01	C4orf22 CMIP FMNL1 LRRC37A4P NSF
Forced vital capacity (FVC)	2.62	11	6	13.3	0.05	8.8e-01	ABCA12 ACP2 CAPZA1 CENPW FMNL1 LRRC37A4P NCOA1 NSF RHOC RP11-1055B8.4 WNT2B
Heel bone mineral density (BMD) T-score, automated (right)	2.81	8	4	8.9	0.57	1.4e-01	ACP2 ARHGAP42 CYB5D1 FAM167A NEIL2 RNASEH2C SIPA1 SLC16A1
Ever unenthusiastic/disinterested for a whole week	1.84	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Heart attack	2.35	3	1	2.2	0.00	1.0e+00	FES SH2B3 ZNF831
Allergy	1.94	5	1	2.2	-0.23	7.1e-01	C6orf106 CLCN6 FES LIME1 SLC22A5
Diabetes (self-reported)	1.82	2	0	0.0	0.00	1.0e+00	C1GALT1 ZBTB46
Hayfever/allergic rhinitis (self-reported)	1.06	1	0	0.0	0.00	1.0e+00	CLCN6
Medication: Ramipril	6.04	8	1	2.2	0.99	8.9e-07	ARHGAP42 C6orf106 CLCN6 CMIP DBR1 FES LSP1 TNNT3
Medication: Simvastatin	3.52	4	1	2.2	0.63	3.7e-01	FES PIGV RNASEH2C ZNF831
Illnesses of siblings	3.77	3	1	2.2	0.00	1.0e+00	ARHGAP42 FES SH2B3
Neuroticism score	2.98	5	5	11.1	0.54	3.5e-01	FAM167A FMNL1 LRRC37A4P NEIL2 NSF
Weight	1.85	9	5	11.1	0.34	3.7e-01	C6orf106 FAM108C1 FAM167A KCNK3 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Impedance of arm (right)	2.47	16	8	17.8	-0.20	4.5e-01	C6orf106 CMIP FAM167A FGF11 FMNL1 HOXA10 LIME1 LRRC37A4P LSP1 MYO9B NEIL2 NSF SH2B3 SLC16A1 SLC4A7 TNNT3
Arm fat percentage (right)	1.91	9	3	6.7	0.09	8.2e-01	C6orf106 CDK10 FAM108C1 FAM167A FGF11 HOXA10 KCNK3 NT5C2 RP11-138A9.1
Trunk fat-free mass	2.21	17	9	20.0	0.11	6.9e-01	ARHGAP42 C6orf106 CENPW CMIP FAM108C1 FGF11 FMNL1 KCNK3 LIME1 MYO9B NCOA1 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Hip circumference	1.77	9	4	8.9	-0.04	9.2e-01	C6orf106 CLCN6 DBR1 FAM108C1 FAM167A KCNK3 NT5C2 RP11-138A9.1 SH2B3
Time employed in main current job	1.24	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Father's age at death	2.68	4	2	4.4	-1.00	3.0e-03	FES MPI SH2B3 SLC22A5
Worrier / anxious feelings	2.26	7	3	6.7	0.10	8.3e-01	C1GALT1 FAM167A FMNL1 LRRC37A4P NEIL2 NSF NT5C2
Hair/balding pattern: Pattern 3	3.85	5	4	8.9	-0.79	1.1e-01	C4orf22 CENPW FMNL1 LRRC37A4P NSF
Number of live births	1.71	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Forced expiratory volume in 1-second (FEV1)	2.70	9	4	8.9	0.05	9.0e-01	ABCA12 ARHGAP42 C1GALT1 FMNL1 LRRC37A4P NCOA1 NSF RHOC RP11-1055B8.4
Qualifications: A levels/AS levels or equivalent	1.34	2	0	0.0	0.00	1.0e+00	LRRC37A4P NSF
Mouth/teeth dental problems: Dentures	0.96	1	0	0.0	0.00	1.0e+00	RP11-1055B8.4
Asthma	2.13	1	1	2.2	0.00	1.0e+00	SLC22A5
Medication: Ibuprofen (e.g. Nurofen)	1.75	3	0	0.0	0.00	1.0e+00	FMNL1 LRRC37A4P NSF
Medication: Cholesterol lowering	3.15	5	1	2.2	0.73	1.6e-01	ARHGAP42 CLCN6 FES PIGV ZNF831
Illnesses of mother	5.25	5	1	2.2	-0.97	4.9e-03	AGT ARHGAP42 FES HOXA10 SLC7A1
Forced expiratory volume in 1-second (FEV1), Best measure	2.46	6	2	4.4	0.41	4.2e-01	C1GALT1 FMNL1 LRRC37A4P NCOA1 NSF RP11-1055B8.4
Impedance of arm (left)	2.63	17	9	20.0	-0.22	4.0e-01	C6orf106 CMIP FAM108C1 FAM167A FGF11 FMNL1 HOXA10 LIME1 LRRC37A4P LSP1 MYO9B NEIL2 NSF SH2B3 SLC16A1 SLC4A7 TNNT3
Arm fat mass (right)	1.73	7	3	6.7	0.43	3.4e-01	C6orf106 FAM108C1 FAM167A HOXA10 KCNK3 NEIL2 NT5C2
Trunk predicted mass	2.21	17	9	20.0	0.11	6.9e-01	ARHGAP42 C6orf106 CENPW CMIP FAM108C1 FGF11 FMNL1 KCNK3 LIME1 MYO9B NCOA1 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Standing height	2.04	22	14	31.1	-0.17	4.5e-01	ACP2 ADRB1 C6orf106 CAPZA1 CENPW FGF11 GTF2B LRRC37A4P LSP1 MGRN1 NCOA1 NSF PIGV RHOC RP11-1055B8.4 SH2B3 SLC16A1 SLC22A5 SLC35F6 SLC4A7 ZNF318 ZNF831
Tense / 'highly strung'	1.68	2	0	0.0	0.00	1.0e+00	FAM167A NT5C2
Hair/balding pattern: Pattern 4	5.79	7	5	11.1	0.64	1.2e-01	C4orf22 CDK10 CENPW FES FMNL1 LRRC37A4P NSF
Birth weight of first child	2.53	5	2	4.4	-0.99	1.6e-03	CLCN6 FES GTF2B MPI SH2B3
Peak expiratory flow (PEF)	2.20	5	2	4.4	-0.35	5.6e-01	ABCA12 C1GALT1 FAM167A LRRC37A4P NSF
Ever highly irritable/argumentative for 2 days	1.63	1	0	0.0	0.00	1.0e+00	LSP1
Qualifications: O levels/GCSEs or equivalent	1.32	1	0	0.0	0.00	1.0e+00	MPI
Blood clot in the leg (DVT)	1.59	1	0	0.0	0.00	1.0e+00	CYB5D1
Medication: Paracetamol	2.18	2	1	2.2	0.00	1.0e+00	LRRC37A4P NSF
Headache pain in last month	2.29	4	3	6.7	-0.99	8.9e-03	FES FMNL1 LRRC37A4P NSF
Medication for cholesterol, blood pressure or diabetes	7.02	13	7	15.6	-0.99	9.1e-11	ACE ACP2 ARHGAP42 C4orf22 CLCN6 FAM108C1 FES PLCB1 RHOC SH2B3 SLC4A7 ZBTB46 ZNF831
Gout (self-reported)	1.65	2	0	0.0	0.00	1.0e+00	SH2B3 SIPA1
Hypothyroidism/myxoedema (self-reported)	2.82	2	2	4.4	0.00	1.0e+00	FAM167A SH2B3
Medication: Amlodipine	9.36	16	8	17.8	0.98	1.7e-12	ACP2 ARHGAP42 CACNB2 CAPZA1 CLCN6 FAM108C1 FES HOXA10 KCNK3 LSP1 RHOC SIPA1 SLC35F6 TNNT3 WNT2B ZNF318
Birth weight	2.48	5	4	8.9	-0.61	2.7e-01	ADRB1 FES NT5C2 SH2B3 TNNT3
High blood pressure (siblings)	5.97	8	2	4.4	0.99	5.1e-06	ACP2 ARHGAP42 CENPW CLCN6 FES RHOC SH2B3 TNNT3
Forced vital capacity (FVC), Best measure	2.40	9	5	11.1	0.14	7.2e-01	ACP2 CENPW FMNL1 LRRC37A4P NCOA1 NSF RHOC RP11-1055B8.4 WNT2B
Body fat percentage	2.11	12	4	8.9	0.12	7.1e-01	C6orf106 CDK10 DBR1 FAM108C1 FGF11 FMNL1 HOXA10 KCNK3 MYO9B NSF RP11-138A9.1 SLC16A1
Leg fat percentage (right)	1.70	5	3	6.7	0.64	2.5e-01	C6orf106 FAM108C1 GTF2B KCNK3 RP11-138A9.1
Arm fat-free mass (right)	2.07	15	5	11.1	0.16	5.8e-01	C6orf106 CENPW CMIP FAM108C1 FGF11 FMNL1 KCNK3 LIME1 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Comparative body size at age 10	1.51	5	0	0.0	0.61	2.8e-01	CMIP FAM167A SIPA1 SLC16A1 ZNF318
Worry too long after embarrassment	1.59	2	0	0.0	0.00	1.0e+00	FAM167A LRRC37A4P
Seen a psychiatrist for nerves, anxiety, tension or depression	1.38	1	0	0.0	0.00	1.0e+00	ADRB1
Wheeze or whistling in the chest in last year	1.53	1	0	0.0	0.00	1.0e+00	ZNF318
Qualifications: College or University degree	1.24	4	2	4.4	-0.13	8.7e-01	GTF2B LRRC37A4P NSF RP11-1055B8.4
Medication for pain relief, constipation, heartburn	2.62	4	2	4.4	-0.49	5.1e-01	ACE C6orf106 FAM108C1 LRRC37A4P
Neck or shoulder pain in last month	1.41	1	0	0.0	0.00	1.0e+00	CENPW
Medication: Blood pressure	10.28	24	14	31.1	0.98	7.0e-17	ACE ACP2 ADRB1 ARHGAP42 C4orf22 CAPZA1 CDK10 CLCN6 CMIP FAM108C1 FES GTF2B HOXA10 LSP1 MPI PLCB1 RHOC SH2B3 SIPA1 SLC4A7 TNNT3 WNT2B ZBTB46 ZNF831
Angina (self-reported)	2.61	1	1	2.2	0.00	1.0e+00	FES
Medication: Ibuprofen	1.71	2	0	0.0	0.00	1.0e+00	FMNL1 LRRC37A4P
Medication: Allopurinol	1.74	4	0	0.0	1.00	4.0e-04	CYB5D1 PIGV SH2B3 SIPA1
Medication: Seretide 50 evohaler	1.36	1	0	0.0	0.00	1.0e+00	SLC22A5
Mean time to correctly identify matches	1.22	2	1	2.2	0.00	1.0e+00	FGF11 SH2B3
Reproduciblity of spirometry measurement using ERS/ATS criteria	1.27	1	0	0.0	0.00	1.0e+00	FMNL1
Whole body fat mass	1.88	8	3	6.7	-0.07	8.7e-01	C6orf106 DBR1 FAM108C1 HOXA10 KCNK3 NT5C2 RP11-138A9.1 SLC16A1
Leg fat mass (right)	1.68	7	3	6.7	0.57	1.8e-01	C6orf106 FAM108C1 FAM167A KCNK3 NEIL2 NT5C2 RP11-138A9.1
Arm predicted mass (right)	2.11	15	5	11.1	0.17	5.5e-01	C6orf106 CENPW CMIP FAM108C1 FGF11 FMNL1 KCNK3 LIME1 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Pulse rate, automated reading	1.40	4	0	0.0	-0.54	4.6e-01	ACP2 C4orf22 C6orf106 RP11-1055B8.4
Alcohol intake frequency.	1.33	3	1	2.2	0.00	1.0e+00	LRRC37A4P MPI NSF
Comparative height size at age 10	2.05	16	6	13.3	-0.03	9.3e-01	ACP2 C6orf106 CACNB2 CENPW FAM108C1 FES GTF2B LRRC37A4P NCOA1 NSF NT5C2 PIGV RP11-1055B8.4 SH2B3 SLC16A1 SLC22A5
Suffer from 'nerves'	1.67	2	0	0.0	0.00	1.0e+00	LRRC37A4P NSF
Overall health rating	1.66	4	0	0.0	0.99	7.7e-03	C6orf106 FAM167A RNASEH2C RP11-1055B8.4
Chest pain or discomfort	1.68	1	0	0.0	0.00	1.0e+00	SIPA1
Medication: Aspirin	3.77	3	1	2.2	0.00	1.0e+00	AGT FES SH2B3
Supplements: Vitamin C	1.28	1	0	0.0	0.00	1.0e+00	NSF
Hypertension (Self-reported)	17.00	56	46	102.2	0.98	1.3e-44	ABCA12 ACE ACP2 ADRB1 AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 CACNB2 CAPZA1 CDK10 CENPW CLCN6 CMIP CYB5D1 DBR1 FAM108C1 FAM167A FES FGF11 FMNL1 GTF2B HOXA10 KCNK3 LIME1 LOC100133545 LRRC37A4P LSP1 MGRN1 MPI MRPL23-AS1 MYO9B NCOA1 NEIL2 NSF NT5C2 PIGV PLCB1 RHOC RNASEH2C RP11-1055B8.4 RP11-138A9.1 SH2B3 SIPA1 SLC16A1 SLC22A5 SLC35F6 SLC4A7 SLC7A1 TNNT3 TRAP1 WNT2B ZBTB46 ZNF318 ZNF831
Gastro-oesophageal reflux (gord) / gastric reflux (Self-reported)	1.78	2	0	0.0	0.00	1.0e+00	C6orf106 FMNL1
Illnesses of father: Heart disease	2.70	3	1	2.2	0.00	1.0e+00	DBR1 FES SH2B3
Smoking status: Previous	1.44	1	0	0.0	0.00	1.0e+00	SH2B3
Forced expiratory volume in 1-second (FEV1), predicted	1.63	3	2	4.4	0.00	1.0e+00	C6orf106 MGRN1 SLC22A5
Whole body fat-free mass	2.11	16	7	15.6	0.08	7.7e-01	ARHGAP42 C6orf106 CENPW CMIP FAM108C1 FGF11 FMNL1 KCNK3 LIME1 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Leg fat-free mass (right)	2.04	13	6	13.3	0.04	8.9e-01	ARHGAP42 C6orf106 CENPW FAM108C1 FAM167A FES KCNK3 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Arm fat percentage (left)	1.95	10	4	8.9	-0.06	8.7e-01	C6orf106 CDK10 FAM108C1 FAM167A FGF11 HOXA10 KCNK3 MRPL23-AS1 NT5C2 RP11-138A9.1
Average weekly red wine intake	0.99	1	0	0.0	0.00	1.0e+00	MPI
Handedness (chirality/laterality): Left-handed	1.96	2	1	2.2	0.00	1.0e+00	LRRC37A4P NSF
Mood swings	2.47	4	3	6.7	0.76	2.4e-01	ACP2 FMNL1 LRRC37A4P NSF
Loneliness, isolation	1.65	2	0	0.0	0.00	1.0e+00	LRRC37A4P SH2B3
Long-standing illness, disability or infirmity	1.59	1	0	0.0	0.00	1.0e+00	DBR1
Diabetes diagnosed by doctor	2.29	4	1	2.2	0.99	1.3e-02	ACE DBR1 RP11-138A9.1 ZBTB46
Mouth/teeth dental problems: Mouth ulcers	1.81	2	1	2.2	0.00	1.0e+00	LRRC37A4P SH2B3
Medication for cholesterol	10.83	29	7	15.6	-0.99	9.9e-27	ACE AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 CAPZA1 CDK10 CENPW CMIP DBR1 FAM108C1 FES HOXA10 LIME1 LRRC37A4P LSP1 MGRN1 PIGV PLCB1 RHOC RNASEH2C RP11-1055B8.4 RP11-138A9.1 SH2B3 SLC16A1 TNNT3 ZBTB46 ZNF831
Back pain experienced in last month	1.48	1	0	0.0	0.00	1.0e+00	C6orf106
Breast cancer (self-reported)	2.09	2	0	0.0	0.00	1.0e+00	LRRC37A4P SLC4A7
Asthma (self-reported)	1.97	1	1	2.2	0.00	1.0e+00	SLC22A5
Medication: Aspirin	3.71	2	1	2.2	0.00	1.0e+00	CDK10 FES
Medication: Gliclazide	1.37	1	0	0.0	0.00	1.0e+00	DBR1
Illnesses of father: None of the above (group 1)	3.49	2	1	2.2	0.00	1.0e+00	FES SH2B3
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.39	4	3	6.7	-0.92	8.0e-02	C1GALT1 FMNL1 LRRC37A4P NSF
Whole body water mass	2.12	16	7	15.6	0.08	7.7e-01	ARHGAP42 C6orf106 CENPW CMIP FAM108C1 FGF11 FMNL1 KCNK3 LIME1 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Leg predicted mass (right)	2.05	13	6	13.3	0.04	9.0e-01	ARHGAP42 C6orf106 CENPW FAM108C1 FAM167A FES KCNK3 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Arm fat mass (left)	1.67	8	3	6.7	0.30	4.7e-01	C6orf106 FAM108C1 FAM167A HOXA10 KCNK3 NEIL2 NT5C2 RP11-138A9.1
Number of self-reported non-cancer illnesses	4.54	8	2	4.4	0.99	7.0e-07	CLCN6 CYB5D1 LIME1 MYO9B SH2B3 SLC22A5 ZNF318 ZNF831
Average weekly champagne plus white wine intake	1.77	2	0	0.0	0.00	1.0e+00	LRRC37A4P NSF
Miserableness	2.09	5	2	4.4	0.31	6.1e-01	ACP2 FAM167A FMNL1 LRRC37A4P NSF
Guilty feelings	1.72	3	1	2.2	0.00	1.0e+00	ACP2 LRRC37A4P NEIL2
Eye problems/disorders: Glaucoma	1.49	1	0	0.0	0.00	1.0e+00	ACP2
Supplements: Fish oil (including cod liver oil)	1.05	1	0	0.0	0.00	1.0e+00	FAM167A
High cholesterol (Self-reported)	2.43	2	1	2.2	0.00	1.0e+00	ARHGAP42 PIGV
Medication: Bendroflumethiazide	11.37	33	10	22.2	0.99	2.0e-30	ACP2 ADRB1 ARHGAP42 C1GALT1 CACNB2 CAPZA1 CDK10 CLCN6 FAM108C1 FAM167A FES FGF11 HOXA10 LOC100133545 LSP1 MGRN1 MPI MRPL23-AS1 MYO9B NEIL2 PIGV PLCB1 RHOC SH2B3 SLC22A5 SLC35F6 SLC4A7 SLC7A1 TNNT3 TRAP1 WNT2B ZNF318 ZNF831
Medication: Paracetamol	2.16	2	1	2.2	0.00	1.0e+00	LRRC37A4P NSF
Medication: Lisinopril	6.02	8	0	0.0	1.00	4.2e-08	ACP2 ARHGAP42 CDK10 LOC100133545 LSP1 MPI MRPL23-AS1 ZNF831
Illnesses of father: High blood pressure	6.00	11	1	2.2	0.97	7.4e-08	ACE ACP2 ARHGAP42 C4orf22 CDK10 CLCN6 FES LSP1 NCOA1 PLCB1 SH2B3
Ever smoked	1.17	1	0	0.0	0.00	1.0e+00	SH2B3
Basal metabolic rate	2.02	11	7	15.6	0.20	5.5e-01	C6orf106 CENPW CMIP FAM108C1 KCNK3 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Leg fat percentage (left)	1.70	6	2	4.4	0.53	2.8e-01	C6orf106 FAM108C1 GTF2B KCNK3 RP11-138A9.1 SLC16A1
Arm fat-free mass (left)	2.07	16	5	11.1	0.21	4.3e-01	C6orf106 CENPW CMIP FAM108C1 FGF11 FMNL1 KCNK3 LIME1 MYO9B NCOA1 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Irritability	2.08	4	3	6.7	-0.99	6.1e-03	FAM167A LRRC37A4P NEIL2 NSF
Risk taking	1.37	2	0	0.0	0.00	1.0e+00	FES KCNK3
Diastolic blood pressure, automated reading	9.96	39	23	51.1	0.96	3.4e-21	ACE ACP2 ADRB1 AGT ARHGAP42 C1GALT1 C4orf22 CACNB2 CAPZA1 CENPW CLCN6 CMIP CYB5D1 DBR1 FAM108C1 FAM167A FES FMNL1 GTF2B HOXA10 LIME1 LSP1 MGRN1 MPI MYO9B NCOA1 NEIL2 NSF NT5C2 PIGV RHOC RNASEH2C SH2B3 SIPA1 SLC16A1 SLC22A5 TNNT3 WNT2B ZNF831
Myopia	1.88	3	0	0.0	0.00	1.0e+00	C1GALT1 CAPZA1 SLC16A1
Vascular/heart problems diagnosed by doctor	16.22	55	38	84.4	-0.98	1.5e-40	ABCA12 ACE ACP2 ADRB1 AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 CACNB2 CAPZA1 CDK10 CENPW CLCN6 CMIP CYB5D1 DBR1 FAM108C1 FAM167A FES FGF11 FMNL1 GTF2B HOXA10 KCNK3 LIME1 LOC100133545 LSP1 MGRN1 MPI MRPL23-AS1 MYO9B NCOA1 NEIL2 NSF NT5C2 PIGV PLCB1 RHOC RNASEH2C RP11-1055B8.4 RP11-138A9.1 SH2B3 SIPA1 SLC16A1 SLC22A5 SLC35F6 SLC4A7 SLC7A1 TNNT3 TRAP1 WNT2B ZBTB46 ZNF318 ZNF831
Cholesterol lowering medication	3.15	4	1	2.2	0.99	1.2e-02	DBR1 MGRN1 PIGV RP11-138A9.1
Pain experienced in last month	1.67	2	0	0.0	0.00	1.0e+00	LRRC37A4P SH2B3
Basal cell carcinoma (self-reported)	1.16	1	1	2.2	0.00	1.0e+00	CDK10
Heart attack/myocardial infarction (self-reported)	2.34	2	1	2.2	0.00	1.0e+00	FES SH2B3
Deep venous thrombosis (DVT) (self-reported)	1.61	1	0	0.0	0.00	1.0e+00	CYB5D1
Heart disease (siblings)	2.10	1	0	0.0	0.00	1.0e+00	FES
Impedance of whole body	2.45	19	9	20.0	-0.24	3.2e-01	ARHGAP42 C6orf106 CENPW CMIP FAM108C1 FAM167A FMNL1 KCNK3 LIME1 LRRC37A4P LSP1 MYO9B NEIL2 NSF NT5C2 SLC16A1 SLC4A7 TNNT3 ZNF318
Leg fat mass (left)	1.66	5	3	6.7	0.72	1.7e-01	C6orf106 FAM108C1 FAM167A KCNK3 NT5C2
Arm predicted mass (left)	2.11	15	5	11.1	0.17	5.5e-01	C6orf106 CENPW CMIP FAM108C1 FGF11 FMNL1 KCNK3 LIME1 MYO9B NCOA1 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	10	0.286	2.0
GTEx	Adipose Visceral Omentum	5	0.246	2.0
GTEx	Adrenal Gland	1	0.069	2.0
GTEx	Artery Aorta	14	0.470	2.1
GTEx	Artery Coronary	0	0.000	1.9
GTEx	Artery Tibial	11	0.292	2.0
GTEx	Brain Caudate basal ganglia	3	0.326	1.9
GTEx	Brain Cerebellar Hemisphere	2	0.134	1.9
GTEx	Brain Cerebellum	6	0.303	1.9
GTEx	Brain Cortex	1	0.097	2.0
GTEx	Brain Frontal Cortex BA9	4	0.433	2.2
GTEx	Brain Hippocampus	1	0.191	1.9
GTEx	Brain Hypothalamus	2	0.339	2.0
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	2.0
GTEx	Brain Putamen basal ganglia	0	0.000	1.8
GTEx	Breast Mammary Tissue	6	0.304	2.1
GTEx	Breast Mammary Tissue (Male)	5	0.419	2.1
GTEx	Breast Mammary Tissue (Female)	6	0.365	2.0
GTEx	Cells EBV-transformed lymphocytes	2	0.141	2.0
GTEx	Cells Transformed fibroblasts	11	0.262	1.9
GTEx	Colon Sigmoid	2	0.137	2.0
GTEx	Colon Transverse	5	0.242	2.0
GTEx	Esophagus Gastroesophageal Junction	0	0.000	2.0
GTEx	Esophagus Mucosa	11	0.331	2.0
GTEx	Esophagus Muscularis	8	0.248	2.0
GTEx	Heart Atrial Appendage	3	0.190	2.1
GTEx	Heart Left Ventricle	3	0.196	2.0
GTEx	Liver	0	0.000	1.8
GTEx	Lung	7	0.244	2.0
GTEx	Muscle Skeletal	7	0.242	1.9
GTEx	Nerve Tibial	9	0.208	1.9
GTEx	Ovary	3	0.330	2.2
GTEx	Pancreas	4	0.245	2.1
GTEx	Pituitary	0	0.000	1.9
GTEx	Prostate	2	0.240	2.1
GTEx	Skin Not Sun Exposed Suprapubic	12	0.488	2.1
GTEx	Skin Sun Exposed Lower leg	11	0.302	2.0
GTEx	Small Intestine Terminal Ileum	0	0.000	2.1
GTEx	Spleen	2	0.142	1.9
GTEx	Stomach	2	0.138	2.0
GTEx	Testis	6	0.190	2.0
GTEx	Thyroid	13	0.325	1.9
GTEx	Uterus	1	0.176	2.1
GTEx	Vagina	2	0.315	1.9
GTEx	Whole Blood	6	0.301	1.9
METSIM	Adipose	11	0.239	1.8
NTR	Blood	4	0.167	1.8
ROSMAP	Brain Pre-frontal Cortex	10	0.228	2.0
YFS	Blood	12	0.260	1.7
CommonMind	Brain Pre-frontal Cortex	14	0.260	1.9
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.181	1.8
The Cancer Genome Atlas	Breast Invasive Carcinoma	16	0.363	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.182	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	6	0.291	1.9
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.292	1.8
The Cancer Genome Atlas	Glioblastoma Multiforme	2	0.196	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	6	0.220	1.9
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	12	0.293	1.9
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.439	1.9
The Cancer Genome Atlas	Brain Lower Grade Glioma	8	0.186	1.8
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	9	0.306	1.8
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	7	0.279	1.8
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.377	1.9
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	1	0.060	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	5	0.377	1.9
The Cancer Genome Atlas	Prostate Adenocarcinoma	6	0.130	1.7
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.9
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.187	1.8
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	2.0
The Cancer Genome Atlas	Stomach Adenocarcinoma	6	0.356	1.9
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	8	0.155	1.7
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.9